Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KLRA
STRONG SELLKailera Therapeutics, Inc. · Healthcare · United States · $2.3B · Avg Vol: $17M/d
9
StockRankGet insider-trade alerts
Q
37
V
25
M
21
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)-7.5%
SMA 50SMA 200
Close
$17.48
RSI (14)
17.8
SCORE BREAKDOWN
Quality
37
ROIC
-24.5%27.6
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-17.7%21.2
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.02x79.7
Current Ratio
9.67x85.9
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-12.5x25.0
P/FCF
—N/A
P/B
-0.0x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
21
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-130%3.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$2.3B
P/E (Forward)
-4.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KLRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc.(you) | $2.3B | 9 | STRONG SELL |
| VERA | Vera Therapeutics, Inc. | $2.5B | 9 | STRONG SELL |
| OCUL | Ocular Therapeutix, Inc. | $1.9B | 9 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | 3 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 16 | STRONG SELL |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 11 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%